From September 2024 to October 2025, there was a 26 percent reduction in infections in adult, pediatric, and neonatal ...

CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter ...

Drivers could face up to £1,000 fines and potential prosecution if they fail to report notifiable medical conditions or ...

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

The Pitt season premiere, "7:00 a.m.," ignores clichés in favor of a gritty, realistic, and uncompromising take on the ...

The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.

CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

The article " Why CorMedix Could be the Biopharma Name to Watch Early in 2026 " first appeared on MarketBeat.

A central line (or central venous catheter) is like an intravenous (IV) line. But it is much longer than a regular IV and goes all the way up to a vein near the heart or just inside the heart. A ...

Please provide your email address to receive an email when new articles are posted on . Of 1,196 tunneled catheters placed in nephrology services that use antibiotics, four resulted in bloodstream ...